Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008

You may also be interested in...



Vaccines, Biosimilars In Shadow As Sun Shines On Ranbaxy?

Sun Pharma may eliminate biosimilars and vaccines work that was being done by Ranbaxy at its two units in Hyderabad and Bangalore. The move could symbolize the thinking of Sun management – to stay away from venturing into product segments that are highly competitive or still evolving.

Vaccines, Biosimilars In Shadow As Sun Shines On Ranbaxy?

Sun Pharma may eliminate biosimilars and vaccines work that was being done by Ranbaxy at its two units in Hyderabad and Bangalore. The move could symbolize the thinking of Sun management – to stay away from venturing into product segments that are highly competitive or still evolving.

Exclusive: Rebuilding Ranbaxy – CEO Says Quality Compliance Trumps Achieving Growth Targets

Undaunted by a spate of negative news, Ranbaxy CEO Arun Sawhney says his mandate is clear: to build a strong reputation for Ranbaxy. In a discussion with PharmAsia News, Sawhney says he regrets the errors of the past that led to quality lapses, but says changes have been made to avoid similar fumbles in the future.

Related Content

UsernamePublicRestriction

Register

SC073043

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel